Skip to main content
Equibles
KOAN logo

KOAN · Resonate Blends, Inc. · Metrics

Track KOAN — free

Use KOAN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KOAN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+25.00%) At close · Oct 19
Rebalance outlook locked
Going-concern doubt — flagged Jun 16, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these financial statements. These consolidated financial statements do not include any adjustments that might arise from this uncertainty.”
View the 10-Q filed Jun 16, 2025
Market Cap
$83,957
Shares
195.25M
Volume · Oct 19 27.79M Avg daily vol (3M) 5.08M

KOAN metrics

53 of 116 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$83,957

Price action

20 metrics
Price change (1W)
+33.3%
Price change (30D)
+33.3%
Price change (3M)
-20.0%
Price change (6M)
-81.0%
Price change (YTD)
-87.1%
Price change (1Y)
-97.5%
Trailing year
Price change (5Y)
-99.9%
52-week high
$0.02
52-week low
$0.00
Change from 52-week high
-97.5%
Change from 52-week low
+100.0%
Annualized volatility
223.5%
Annualized volatility (3M)
—
Beta
-0.1
RSI (14D)
55.9
Price vs SMA 50
+9.9%
Price vs SMA 200
-75.0%
Avg volume (3M)
4.63M
Relative volume
5.6
Average dollar volume
$1,761

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
195.25M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 5,000.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.0×
reciprocal yield 2,658.4%
P / book
—
FCF yield
-1,270.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
1,361.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
65.5%
Operating margin
-72.2%
Trailing 12 months
Net margin
51.2%
Gross profit (TTM)
$1.46M
Operating profit (TTM)
−$1.61M
Net income (TTM)
$1.14M
Trailing 12 months
Diluted EPS (TTM)
$0.02
FCF margin
-47.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.02

Growth

11 metrics
Revenue growth YoY
+353.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.23M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+19.3%
Year over year · more shares
Revenue CAGR (3Y)
+312.4%
Revenue CAGR (5Y)
+12.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
95.1%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$1.68M
Free cash flow (TTM)
−$1.07M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$18,117
Total assets
$1.20M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.07M
Capital expenditures (TTM)
$1,000
R&D (TTM)
—
SG&A (TTM)
$181,931
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 897078 CUSIP 76090M102 Visit website